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The respiratory diseases caused by rhinovirus, respiratory syncytial virus, and influenza
virus represent a large social and financial burden on healthcare worldwide. Although all
three viruses have distinctly unique properties in terms of infection and replication, they
share the ability to exploit/manipulate the host-cell nucleocytoplasmic transport system
in order to replicate effectively and efficiently. This review outlines the various ways
in which infection by these viruses impacts on the host nucleocytoplasmic transport
system, and examples where inhibition thereof in turn decreases viral replication. The
highly conserved nature of the nucleocytoplasmic transport system and the viral proteins
that interact with it make this virus–host interface a prime candidate for the development
of specific antiviral therapeutics in the future.
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Introduction: the Global Health Problem
Viral respiratory disease (VRD) results in the hospitalization and deaths each year of millions of
people worldwide, representing a large social and ﬁnancial burden on healthcare globally. Although
100s of viruses can potentially cause VRD, the main causative agents are, Inﬂuenza virus, RSV,
and HRV. Inﬂuenza virus, an orthomyxovirus, is responsible for an estimated 3–5 million cases
of severe illness and 250–500 thousand deaths worldwide per year, with an economic impact of
$87.1 billion in the US alone (Molinari et al., 2007). During an epidemic/pandemic year, such as
the recent 2009 H1N1 outbreak, these ﬁgures can rise dramatically; an estimated 42–86 million
cases of infection were reported in 2009 (Centers for Disease Control and Prevention, 2010).
The pneumovirus RSV is the single greatest cause of lower respiratory tract illness (LRTI) and
bronchiolitis in infants and the elderly, with an estimated 64 million infectious cases and 160,000–
600,000 deaths recorded worldwide each winter (Falsey et al., 1995; Law et al., 2002; Simoes, 2008;
WHO, 2009; Krilov, 2011). RSV related disease represents a cost of US$2.4 billion in the US alone
(Tran et al., 2013). The Picornavirus HRV, is the primary causative agent of the “common cold,”
resulting in upper respiratory tract infection (URTI) that is generally cleared; although severe
Abbreviations: DAF, decay accelerating factor; Flu, inﬂuenza; HRV, human rhinovirus; ICAM-1, intercellular adhesion
molecule-1; IFN, interferon; IMP, importin; ISG, interferon stimulated gene; ISRE, interferon stimulated response element;
LDLR, low density lipoprotein receptor; LRTI, lower respiratory tract infection; MDA-5, melanoma-diﬀerentiation-
associated gene 5; NE, nuclear envelope; NES, nuclear export signal; NPC, nuclear pore complex; NLS, nuclear localization
signal; Nup, nucleoporin; PAMPs, pathogen associated molecular patterns; RIG-I, retinoic-acid-inducible protein; RSV,
respiratory syncytial virus; SINE, selective inhibitors of nuclear export; TLR, toll-like receptors; URTI, upper respiratory
tract illness; VRD, viral respiratory disease; vRNA, viral RNA; vRNP, viral ribonucleoprotein complex; XPO, exportin.
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complications can arise in vulnerable individuals including
the elderly, but especially those with underlying respiratory
conditions such as asthma (Nicholson et al., 1993; Costa et al.,
2014), where HRV has been identiﬁed as the causative agent in
50–85% of virally induced asthma hospitalization cases, costing
billions of dollars (Costa et al., 2014).
Inﬂuenza virus, RSV, and HRV alone represent a huge
burden of disease and economic strain worldwide. Unlike
inﬂuenza virus, where a seasonal vaccine is available, there are
currently no eﬃcacious vaccines or treatments for either RSV
(Bawage et al., 2013) or HRV (Jacobs et al., 2013). Research
over the past decade indicates that many cytoplasmically
replicating RNA viruses, such as RSV and HRV, utilize and/or
manipulate the host-cell nuclear transport machinery to their
beneﬁt, either by transporting speciﬁc viral proteins into the
nucleus to modulate cellular function/minimize the host antiviral
response, or by inhibiting host nuclear transport itself and
thereby dampening innate immune responses (Alvisi et al.,
2007; Fulcher and Jans, 2011). In the case of inﬂuenza virus,
nuclear transport, and localization of key viral proteins is
required for vRNA replication to occur, which is subsequently
exported from the nucleus (Whittaker et al., 1996; Neumann
et al., 1997; Samji, 2009; Huet et al., 2010). The importance
of the host-cell nucleocytoplasmic transport machinery to viral
infection makes it a therapeutic target of great potential for
development of anti-viral agents in the future (Perwitasari et al.,
2014).
Nuclear Transport
Gaining Access to the Nucleus
The nucleus is a specialized compartment within eukaryotic cells
where the genetic information is contained, surrounded by the
lipid double membrane structure of the NE representing the
boundary between the genome and the cytoplasm (Dingwall
and Laskey, 1992). Speciﬁc mechanisms are required to
eﬀect the transport of proteins, mRNA, and protein–RNA
complexes between the cytoplasm and the nucleus in a
controlled and regulated manner (Jans and Hubner, 1996).
In order to permit the necessary passage of proteins and
mRNA into and out of the nucleus, the NE is perforated
by a series of NPCs through which all transport into
and out of the nucleus occurs. These channels comprise
up to 50 diﬀerent nup proteins (8–32 copies of each;
Rout et al., 2000) resulting in a super-protein-complex of
around 125 MDa (Reichelt et al., 1990). Speciﬁc nups harbor
hydrophobic (Phe-Gly or FG) repeat sequences, which are
believed to function as transient binding sites for complexes
passing through the NE. The NPC acts as a molecular sieve,
enabling the passage of molecules <50 kDa in molecular
weight into or out of the nucleus by passive diﬀusion
(Talcott and Moore, 1999). Larger molecules can only be
transported through the NPC in an active energy-dependent
mechanism requiring speciﬁc targeting signals, NLS and
NES, which mediate transport into and out of the nucleus,
respectively.
Signal-dependent protein nuclear import (see Figure 1) is
mediated by members of the IMP superfamily of transporters,
of which various α and β subtypes exist that recognize
and bind to speciﬁc and highly conserved NLSs on their
respective cargo proteins (Conti et al., 1998); generally through
either the classical IMPα/β1 heterodimer (see Figure 1ia)
or one of the IMPβs alone (Figure 1ib; Jans and Hubner,
1996; Alvisi et al., 2007; Fulcher and Jans, 2011). The NLS-
cargo/IMP complex then docks to nups at the cytoplasmic
side of the NPC (Figure 1ii), before translocating through
the pore via transient and sequential interactions between
IMPβ and the nups (Figure 1iii; Bednenko et al., 2003).
Once within the nucleus, RanGTP binds to IMPβ (Figure 1iv)
resulting in NLS-cargo release (Stewart, 2007). The nuclear
IMPs are then recycled to the cytoplasm where they are
available for subsequent rounds of import (Kutay et al., 1997).
In analogous fashion to import, the nuclear export of NES-
containing proteins is mediated by the XPO family of homologs
of IMPβ1, of which XPO1 is the best-characterized (Hutten
and Kehlenbach, 2007). Brieﬂy, RanGTP binding to the XPO
(Figure 1v) is required to allow potential cargo proteins to
bind. The RanGTP/XPO/cargo trimeric complex then passes
through the NPC (Figure 1vi) to the cytoplasm via sequential
interactions between the XPO and nups of the NPC. Once in
the cytoplasm, hydrolysis of RanGTP to RanGDP (Figure 1vii)
eﬀects release of the NES containing cargo protein into the
cytoplasm.
Nucleocytoplasmic Transport and the Innate
Immune Response to Viral Infection
Viral respiratory tract infections represent one of the most
common types of infectious disease(s) encountered, so it is
imperative that the host innate immune response is able to
identify and eliminate these threats eﬃciently. During viral
infection, the family of TLRs (Thompson and Locarnini, 2007)
in concert with the cellular helicases RIG-I andMDA-5 recognize
diﬀerent viral by-products, or PAMPs, which initiates a cascade
of events resulting in the activation of transcription factors
such as IFN response factor 3 (IRF3; Hiscott, 2007), nuclear
factor κB (NF-κB; Fagerlund et al., 2005) or activating protein 1
(AP1). These transcription factors are transported to the nucleus
through their interaction with speciﬁc IMPs (Torgerson et al.,
1998), resulting in the initiation of IFN-β transcription. Newly
translated IFN-β protein is then secreted from the cell to work
in an autocrine and paracrine matter, whereby binding to the
IFN-α/β receptor leads to a secondary cascade of events involving
multiple proteins and transcription factors such as the STAT
(signal transducer and activator of transcription) proteins. These
proteins are transported to the nucleus in an IMP mediated
manner where they interact with IFN-sensitive response elements
(ISRE), activating the transcription of numerous anti-viral IFN
stimulated genes (ISGs). Clearly, it is imperative that host-cell
nuclear import remains functional during a viral infection for
a concerted immune response to be initiated. With regulated
host-cell nuclear transport playing such a critical role in the
innate immune response, this system is therefore ripe for
attenuation/modulation by infectious pathogens.
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FIGURE 1 | Schematic representation of mammalian cell
nucleocytoplasmic transport. Nuclear transport across the NE requires
the recognition and binding of NLS-containing cargo proteins by either the
IMPα/β1 heterodimer (ia) or IMPβ homologues alone (ib) on the
cytoplasmic side of the NPC. Once bound (ii), the transport complex is
believed to dock to the cytoplasmic side of the NPC and then move
through the NPC (iii) via a series of transient interactions between IMPβ
and the nups that comprise the NPC. Once within the nucleus, binding of
RanGTP (iv) to Impβ causes dissociation of the transport complexes and
release of the cargo to perform its nuclear function. Nuclear export (v)
requires the recognition of a nuclear export sequence (NES)-containing
cargoes by an XPO such as XPO1 in complex with RanGTP. The trimeric
RanGTP/XPO1/cargo complex passes through the NPC via a series of
transient interactions (vi) with nups within the NPC. Once within the
cytoplasm, hydrolysis of RanGTP to RanGDP (vii) results in dissociation of
the XPO1/cargo complex.
Viral Replication and Interaction(s) with
Host-Cell Nucleocytoplasmic Transport
Human Rhinovirus (HRV)
Human rhinovirus, a member of the picornaviridae family, is
a non-enveloped icosahedral virus that at its core possesses
a positive sense single-stranded RNA (+ssRNA) genome that
encodes 11 proteins initially expressed as a single polyprotein.
To date there have been 156 diﬀerent HRV serotypes identiﬁed
(divided into serotypes A–C based on the phylogenetic
relationship of the respective VP1 and VP2/4 genes; McIntyre
et al., 2013). Current understanding is that the majority of
HRV A/B serotypes can bind speciﬁcally to ICAM-1 on the
host cell surface (Greve et al., 1989), with approximately 10%
utilizing the LDLR (Hofer et al., 1994). A very small subset
appear able to utilize the DAF protein (Blomqvist et al., 2002)
to bind target cells, while the Cadherin-related family member
3 (CDHR3) has only recently been identiﬁed as the cell surface
receptor used by HRV-C serotypes (Bochkov et al., 2015).
Viral binding and attachment to the host-cell has traditionally
been viewed as a viable target for drug development, but
the fact that at least four diﬀerent cell-surface receptors are
used by HRV serotypes means that a pan-serotype inhibitor
of HRV binding is unlikely to be a realistic possibility in the
near future. Rhinovirus infection is initiated by inhalation of
HRV into the nasal passage whereby the virions make their
way to the rear of the nose where they bind one of the
respective cell surface receptors. Upon binding the virions
are internalized by either clathrin-dependent endocytosis or
macropinocytosis (reviewed in Fuchs and Blaas, 2010), after
which viral uncoating occurs, and the +ssRNA genome is
released into the cytoplasm where it is translated on entry
to produce a single polyprotein. The polyprotein undergoes
self-proteolysis during translation by the viral proteases 2A
and 3C (Skern et al., 1985; Cordingley et al., 1990) to
generate the structural (VP1, VP2, VP3, VP4) and non-
structural (2A, 2B, 2C, 3A, 3B, 3C, 3D) proteins required for
virion assembly, meaning that the full-length product is rarely
observed.
In recent years, a hallmark of picornavirus, and thus
HRV infection, is the shutdown of regulated host-cell
nucleocytoplasmic transport (see Figure 2), contributing to
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FIGURE 2 | Schematic representation of VRD modulation and/or
exploitation of host nucleocytoplasmic transport processes. Inhibition
and/or utilization of host-cell nucleocytoplasmic transport are key features of
infection by Rhinovirus (HRV), Influenza virus and RSV. During HRV infection,
the viral proteases 2A and 3C localize to the NPC (i) and degrade nups 62,
98, 153, 214, and 358, causing mislocalization of nuclear proteins such as
nucleolin (ii) and preventing nuclear import of complexes such as the
anti-viral NF-κB transcription factor (iii). Host-cell transcription/translation is
severely reduced by the NLS of the 3CD and 3CD’ proteases which degrade
the general transcription factor OCT-1 (iv) in concert with 2A, which also
degrades the cytoplasmic translation elongation factors eIF4GI and eIF4GII2A
(v). Efficient influenza virus replication requires the transport of the viral
genome and proteins required for its replication (PB1, PB2, PA, and NP) to
the nucleus where they form a vRNP complex. The vRNA is transported to
the nucleus through binding to NP, which is recognized by IMPα1 or α5 (vi)
in complex with Impβ1 (x), is transported through the NPC, as is PB2 (vii),
which is recognized by either IMPα7, α5, α3, or α1 in complex with IMPβ1
(x). The PB1/PA heterodimer is transported to the nucleus by interaction with
the IMPβ1 homologue IPO5 (viii) which can bind the NPC directly. The M1
protein, critical for the nuclear export of the vRNP complex is imported to
the nucleus via IMPα1/β1 (ix,x). The newly synthesized vRNA (part of the
vRNP-N1-NS2 complex) is exported from the nucleus by XPO1 interaction
with NS2 (xi). An unknown exporter (xii) that interacts with M1 has been
implicated in this process, as have the proteins Hsc70 and NXF1/TAP (xiii),
which are postulated to act as cofactors via an undefined mechanism. The
RSV M protein relies on interaction with Impβ1 (xiv) early during infection to
localize to the nucleus where it suppresses host-cell transcription by
potentially blocking the activity of transcription factors such as ZNF502 and
YY1 (xv). M is exported to the cytoplasm later in infection by XPO1 (xvi),
where it is critical for pro-virion assembly.
reduced cellular transcription and translation, although viral
transcription/translation continues unabated. The disruption
of host-cell nuclear transport has been attributed to the speciﬁc
proteolysis and degradation of the FG-containing nups 62,
98, and 153 within the NPC by the viral proteases 2A and 3C
(Ghildyal et al., 2009b; Park et al., 2010; Watters and Palmenberg,
2011; Walker et al., 2013; see Figure 2i), leading to disruption of
classical nucleocytoplasmic shuttling (Gustin and Sarnow, 2002;
see Table 1). The general disruption of nuclear transport can be
observed early in HRV infection whereby endogenous nuclear
proteins such as the RNA associated La and Sam68 proteins
(Itoh et al., 2002; Wolin and Cedervall, 2002) are mislocalised
to the cytoplasm, along with the critical ribosome maturation
factor, nucleolin (Figure 2ii; Gustin and Sarnow, 2002) leading
to cell-cycle arrest and subsequent apoptosis (Ugrinova et al.,
2007). In an in vitro semi-intact cell system, GFP-tagged 3C
was found to disrupt both active (IMP-mediated) and passive
(size exclusion) nuclear transport through degradation of nups
358, 214, and 153 (Ghildyal et al., 2009b). Interestingly, nup62
was not degraded, implying that proteolysis of speciﬁc nups
within the NPC may be through the concerted action of 2A
and 3C.
In addition to its role in nup degradation, 3C in the context
of the larger 3CD and 3CD’ precursors appears to localize in
the nucleus and degrade the general transcription factor OCT-
1 (see Figure 2iv; Amineva et al., 2004), leading to a rapid loss of
host-cell transcription early in infection (2–4 h). In parallel, the
eukaryotic initiation factors (eIFs) eIF4GI and eIF4GII2A, which
form part of the eIF4F complex that recognizes capped-RNA, are
degraded by 2A (Figure 2v) further contributing to halting host-
cell translation (Liebig et al., 2002) but not IRES-mediated HRV
RNA translation.
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TABLE 1 | Summary of respiratory virus protein interactions with components of the host nucleocytoplasmic transport system.
Virus Viral
Protein
Host
protein
Effect of interaction Effect of disrupting interaction
on virus titre
Reference
Rhinovirus 2A nup62 Disruption of host
nucleocytoplasmic transport
N/A Gustin and Sarnow
(2002)
2A nup98
2A/3C nup153
2A/3C nup214/358
RSV M IMPβ1 IMPβ1 transports M to nucleus
to initiate host-cell
transcriptional inhibition and
increase virus production
Mutation of M NLS results in 20-fold
reduction in virus titre
Ghildyal et al.
(2005a)
M XPO1 Nuclear export of M by XPO1 is
absolutely essential to initiate
virion formation
Mutation of M NES abolishes RSV
virus production; inhibition of XPO1
mediated nuclear export using the
XPO1 inhibitor LMB reduces RSV
titre > 10-fold
Ghildyal et al.
(2009a)
Influenza NP IMPα1,
IMPα5
NP binding to α1 or β5 allows
nuclear import of NP through
Impβ1
Cells treated with peptides that
compete with NP binding for Impα
show 2–5 log reduction in Flu virus
titre. Granzyme K mediated
proteolysis of Impα/β reduced NP
nuclear import and subsequent Flu
viral titre twofold
O’Neill et al. (1995),
Cros et al. (2005)
PB1 IMPβ3 PB1 (heterodimer with PA)
binds to IMPβ3 and is trafficked
to the nucleus
Mutation of the IMPβ3 recognised
NLS in PB1 results in a 4-log10
reduction in virus titre
Hutchinson et al.
(2011)
PB2 IMPα1, α3,
α5, α7
PB2 shows preference for
IMPβ7 in mammalian cells in
vivo, but it can bind to IMPα3
and α5
Mutation of PB2 NLS results in
100-fold reduction in virus titre
Resa-Infante et al.
(2008), Boivin and
Hart (2011),
Pumroy et al.
(2015)
PA IMPβ3 Requires heterodimerization
with PB1 to undergo nuclear
import by IMPβ3
Mutation of the IMPβ3 recognised
NLS in PB1 results in a 4-log10
reduction in virus titre
Hutchinson et al.
(2011)
NS2
(NEP)
XPO1 Allows nuclear export of
vRNP-M1-NS2 complex from
nucleus to cytoplasm where
viral budding occurs
The XPO1 inhibitor LMB almost
completely suppresses influenza
virus levels in infected MDCK cells.
XPO1 inhibitor Verdinexor inhibits
influenza virus A and B replication in
tissue culture and a mouse model.
Watanabe et al.
(2008), Brunotte
et al. (2014), Gao
et al. (2014),
Perwitasari et al.
(2014)
M1 IMPα1
(porcine)
M1 shows interaction with
porcine IMPα1, but this has yet
to be confirmed in human cells
N/A Liu et al. (2014)
Exporter (?) Leucine-rich NES region
identified in M1. Mutation
causes accumulation of vRNP
in the nucleus, even in the
presence of NS2
Alanine mutation of the M1 NES
reduced Flu viral titre 200–300-fold
Cao et al. (2012)
vRNP-
M1-NS2
Hsc70 Hsc70 has been shown to
interact with M1 and may help
mediate vRNP nuclear export in
the absence of NS2
Watanabe et al.
(2014)
NXF1/TAP NXF1/TAP is required for the
nuclear export of viral mRNA
encoding HA, NA, M1, NS1,
and M2
siRNA depletion of NXF1 reduced
Flu viral titre 100-fold
Read and Digard
(2010)
IMP, importin; nup, nucleoporin; LMB, leptomycin B.
During HRV infection, the production of INF-β mRNA
through the Type 1 IFN response is attenuated, leading to
dampening of the antiviral response (Kotla et al., 2008). Although
the precise mechanism leading to the cause of this reduced
response has yet to be elucidated, it is entirely plausible that
the deregulation of host nucleocytoplasmic transport by the
2A and/or 3C proteases may be responsible, by preventing the
nuclear import of activated NF-kB (Figure 2iii). Although the
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precise role(s) and kinetics of 2A and 3C protease-mediated nup
degradation remain to be determined in vivo, it is clear that
disruption and degradation of the NPC and cleavage of essential
transcription factors by 3C is central to host cell shutdown,
through deregulation of host cell nucleocytoplasmic transport to
prevent the infected cell mounting an antiviral response.
Respiratory Syncytial Virus (RSV)
In a similar fashion to HRV, the paramyxovirus RSV replicates
entirely within the cytosol of infected cells. The outer surface
of the RSV virion is comprised of a lipid-rich membrane that
encompasses the nucleocapsid within which resides the ssRNA
viral genome that encodes all 11 viral proteins (Ogra, 2004).
Although glycosaminoglycans are utilized in cell culture (Hallak
et al., 2000a,b), clinical RSV infection is initiated by binding of the
large glycoprotein (G; Levine et al., 1987) on the virion surface
to as yet uncharacterized cell-surface receptor(s). A potential
candidate in this regard appears to be the nucleolar protein
nucleolin, believed to be present on the apical surface of lower
respiratory tract epithelia (Tayyari et al., 2011); see also (Holguera
et al., 2014). Following attachment, the viral fusion (F) protein
causes both viral and cellular membranes to fuse, subsequently
releasing the ssRNA containing nucleocapsid core into the host
cell cytoplasm and allowing viral transcription/translation to
proceed.
A key pathogenic factor and component of RSV is the
virally derived Matrix (M) protein, which associates with the
nucleocapsid and envelope glycoprotein complexes within the
virion, and is believed to be a key driver of virus assembly in
the infected cell (Ghildyal et al., 2006, 2009a). In addition to
this important role, M is also able to traﬃc early in infection
to the host cell nucleus (Figure 2xiv), dependent on interaction
with IMPβ1 (Ghildyal et al., 2005a; see Table 1). Nuclear M
inhibits host cell transcription (Figure 2xv; Ghildyal et al., 2003),
potentially by targeting transcription factors such as the Zinc
ﬁnger-containing ZNF501 and ZNF502, or the ubiquitous YY1
(Yin Yang 1; Kipper et al., 2015).
Later in infection, M is ferried to the cytoplasm by XPO1
(Figure 2xvi; Ghildyal et al., 2009a), where it localizes to viral
inclusion bodies (IBs; Liﬂand et al., 2012), and functions as
an adaptor bringing together newly formed nucleocapsids and
envelope glycoproteins F and G (Ghildyal et al., 2002, 2005b,
2006) to eﬀect virus assembly. Although RSV replication and
assembly occurs exclusively within the cytoplasm, RSV virus with
mutations within M’s IMPβ1-recognized NLS are approximately
20-fold attenuated in terms of virus production (Ghildyal et al.,
2009a), indicating that M nuclear import through IMPβ1 is
central to RSV infection, and represents a viable target for the
development of agents to combat RSV infection. Analogously,
M nuclear export through XPO1 is an interesting target based
on the fact that RSV mutated in the XPO1-recognized NES of
M is not viable, presumably due to the critical requirement for
M in the cytoplasm later in infection for RSV virion assembly
(Ghildyal et al., 2009a); inhibition of XPO1 using the XPO1
speciﬁc inhibitor leptomycin B (LMB) added later in infection
reduces RSV virus production 20-fold, underlining the utility
of targeting M nuclear export as an approach to inhibit RSV
(Ghildyal et al., 2009a).
Influenza (Flu)
Unlike RSV and HRV, which replicate their viral genomes
within the host-cell cytoplasm, Inﬂuenza virus must transport
its genome, in the form of a RNP complex, into the host-cell
nucleus in order for replication to occur. The key components
of the RNP are the vRNA binding nucleoprotein (NP; O’Neill
et al., 1995) and the vRNA-dependent RNA polymerase (vRdRp),
which comprises the three subunits, PB1, PB2 (protein basic 1
and 2) and polymerase acidic (PA). NP-dependent nuclear import
of vRNA appears to be through interaction of NP with either
IMPα1/β1 or α5/β1 (Figure 2vi; O’Neill et al., 1995; Wu et al.,
2007). Nuclear import of the PB1/PA heterodimer is mediated
through recognition of PB1 by IMPβ3 (IPO5; Figure 2vii; Deng
et al., 2006; Hutchinson et al., 2011). Finally, PB2 is able to
interact with a number of diﬀerent IMPs, including IMPα7/β1,
α1/β1, α3/β1, and α5/β1, all of which can transport it into the
nucleus (Figure 2vii; Resa-Infante et al., 2008; Boivin and Hart,
2011; Pumroy et al., 2015). Thus, various IMPs are responsible
for nuclear import of the various proteins that make up the
mature vRNP complex, meaning that there are potentially many
candidate NLS:IMP targets for therapeutic intervention early in
the viral lifecycle (see Table 1).
Once the vRNP is localized within the host-cell nucleus,
the vRNA initially undergoes a round of replication resulting
in the production of 5′ capped and 3′ poly(A) viral mRNA
which is exported to the cytosol utilizing the host-cells mRNA
transport machinery to undergo translation to produce new viral
proteins. A second round of replication then proceeds, whereby
positive sense RNAs are produced to serve as templates for the
production of negative sense vRNA genomes, which in turn
combine with newly synthesized and nuclear localized NP, PB1,
PB2, and PA proteins to form new vRNPs (Josset et al., 2008).
These vRNPs undergo nuclear export through the action of the
viral NS2 (NEP) and M1 proteins that enter the nucleus either
via passive diﬀusion, or potentially through IMPα1 in the case
of M1 (Figure 2ix; Table 1; Liu et al., 2014), and recruit the
host export protein XPO1. XPO1 recognizes the vRNP-M1-NS2
complex (Figure 2xi) via 2 NESs on NS2, which helps eﬀect
transport of the complex out of the nucleus via the NPC. M1
also appears to contribute to vRNP nuclear export through a NES
that would appear to be recognized by an export protein other
than XPO1 (Figure 2xii; see Table 1); mutation of the NES results
in vRNPs nuclear accumulation (Cao et al., 2012). Additionally,
two recent studies have identiﬁed additional cellular proteins
as co-factors (Figure 2xiii) for vRNP-M1-NS2-XPO1 export
(Table 1); the heat shock protein Hsc70 (Watanabe et al., 2014),
which is believed to play a key role in calcium-/calmodulin-
dependent nuclear import of SOX proteins nuclear import (Kaur
et al., 2013), and NXF1/TAP (Read and Digard, 2010), integrally
involved in the nuclear export of cellular mRNA. These may
also represent potential candidates for antiviral intervention.
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Clearly, the host-cell nucleocytoplasmic transport machinery
is absolutely required during multiple stages of the Inﬂuenza
virus life cycle, with both nuclear import and export of vRNPs
presenting targets for potential antiviral intervention (Perwitasari
et al., 2014).
Current Therapeutics
Although there are currently a number of therapeutic and
prophylactic approaches to manage HRV, RSV, and Flu, there is
an ever-present need for new speciﬁc and low toxicity treatments
for all three.
A number of diﬀerent treatment regimens targeting the HRV
viral capsid and protease proteins have been trialed in the past
(De Palma et al., 2008), but none have had any appreciable
eﬀect on HRV disease severity (Jacobs et al., 2013). Vapendavir, a
capsid binding small molecular inhibitor is currently undergoing
Phase 2b clinical trials, with encouraging preliminary data
(Matz, 2013), however, as for previous drugs targeting the
viral capsid, which is less highly conserved across HRV strains
than the other non-structural proteins, there remains a strong
likelihood of selection for viral escape mutants (Thibaut et al.,
2012). In contrast, the viral proteases 2A and 3C are highly
conserved between HRV serotypes (Tapparel et al., 2007) and
represent the most likely candidates for successful therapeutic
intervention. The most promising HRV protease inhibitor thus
far has been Rupintrivir, which speciﬁcally recognizes and
irreversibly binds a domain within protease 3C that is highly
conserved in all picornavirus species (Binford et al., 2007).
Although promising results have been obtained in vitro and
in early challenge trials, a signiﬁcant reduction in viral load
was not achieved during trials with natural infection due
to the requirement for the drug to be taken immediately
prior or just after infection (Patick et al., 2005); thus further
development in regards to HRV was ceased. Recently the
enterovirus 3C protease inhibitor SG85 was shown to eﬀectively
inhibit HRV infection, with little evidence for resistance arising
under long-term serial passage of virus in a tissue culture
system in the presence of the drug (Lacroix et al., 2015).
Although few small molecular inhibitors have been developed
targeting proteases 3C or 2A (Patick et al., 2005), recent studies
show that these may prove be a promising avenue in the
future.
There is no vaccine currently available against RSV, with
previous approaches having caused increased sensitivity and
morbidity of premature babies to RSV (Fulginiti et al., 1969).
There are currently two prophylactics available, which are able
to be safely administered to individuals identiﬁed as high-
risk of complications if infected with RSV. The monoclonal
antibody Palivizumab targets the RSV F protein, and can be
administered to pre-identiﬁed high-risk infants such as those
with chronic lung/heart disease or premature babies (Chavez-
Bueno et al., 2007; American Academy of Pediatrics Committee
on Infectious and American Academy of Pediatrics Bronchiolitis
Guidelines, 2014). Palivizumab can be administered monthly for
a maximum of 5 months to maintain therapeutic levels over
winter (Saez-Llorens et al., 1998), but although it has helped
reduce hospitalization of “at-risk” individuals, it is unsuitable as
a large-scale, community wide prophylactic, due to logistic issues
and high cost due to the frequency of dosing required (La Via
et al., 2013). A more potent derivative, Motavizumab was initially
thought to reduce RSV hospitalizations by 25%, compared to
those treated with Palivizumab (Feltes et al., 2011), but a recent
study of 118 RSV-infected infants has shown that Motavizumab
had no appreciable eﬀect on the duration of hospitalization,
severity of illness, or wheezing episodes compared to placebo
(Ramilo et al., 2014).
The nucleoside Ribavirin in aerosol form has also been
prescribed to treat RSV, but appears to have only a moderate
eﬀect in terms of reducing days of hospitalization and recurrent
wheezing post RSV infection (Ventre and Randolph, 2007).
Ribavirin is also extremely costly (∼US $14,000 per treatment)
in aerosol form, making it unsuitable for use in impoverished
countries (Pelaez et al., 2009). Finally, apart from being
carcinogenic and gonadotoxic (Narayana et al., 2005), it appears
to be a potential teratogen for women of childbearing age who
may come into contact with the drug via secondary exposure
(e.g., those caring for children receiving Ribavirin treatment;
Krilov, 2002). Clearly, the lack of a vaccine, and limitations
of current antiviral prophylactics and therapeutics underline
the need for safer, low toxicity and low cost antivirals for
RSV.
In contrast to RSV, current options to treat Flu include
vaccines and anti-virals. Vaccines, although highly successful, are
only able to protect against those viruses that are antigenically
close to the vaccine viral reference strain used. Thus, in cases
such as the 2009 H1N1 pandemic, vaccine production and lead
time was 3–6 months, requiring the use of antiviral agents
in the interim (Organization, 2009). The two main classes
of anti-inﬂuenza virus compounds commercially available are
neuraminidase (NA) inhibitors and M2 ion channel blockers.
The glycoprotein NA is located within the viral envelope and
plays a crucial role in viral particle release from infected cells
and prevents virus self-aggregation (Itamura, 1997; Yano et al.,
2008; Shtyrya et al., 2009). Historically, NA has been a viable,
druggable target due to its high conservation amongst inﬂuenza
virus strains (Yen et al., 2006), surface accessibility and low rate
of mutation compared to other viral proteins, but resistant viral
strains have started to appear in the last few years (Garcia et al.,
2009).
Inﬂuenza virus M2 protein forms a transmembrane pore that
helps control the acidity of the virion interior and facilitate viral
fusion and release of the genome-containing core. Numerous
drugs of the adamantine family have been developed over the
last ﬁve decades (Davies et al., 1964; Grunert et al., 1965; Tyrrell
et al., 1965) that block the action of this pore, although their use
is falling out of favor due to the rapid occurrence of resistant
viral strains (Leonov et al., 2011). Thus, with use of the two
major classes of inﬂuenza anti-virals becoming more and more
problematic, it is imperative that new, broad-spectrum anti-viral
agents be developed.
As indicated above, nucleocytoplasmic transport is integral
to the majority of the inﬂuenza virus replicative cycle. Previous
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studies have looked at the eﬀect of attenuating the nuclear
transport of various inﬂuenza virus proteins as an antiviral
approach. Peptides derived from IMPα have been used in a
competition approach to reduce the level of nuclear NP, resulting
in a dose-dependent reduction in viral titre by decreasing
inﬂuenza vRNA nuclear import (Cros et al., 2005). In addition,
results from a reverse genetics system indicate that mutation of
the well-conserved IMPβ3-recognized NLS1 and NLS2 region
of PB1 results in severely attenuated/impaired viral replication
(Hutchinson et al., 2011). Finally, speciﬁc proteolysis of Impα/β1
by Granzyme K in inﬂuenza virus-infected A549 cells both
impaired NP nuclear import and reduced viral titres by 50%
(Zhong et al., 2012), highlighting that the nuclear import of the
vRNP can be a viable target for therapeutic intervention.
Exportin1-mediated nuclear export has been identiﬁed as
critical for eﬃcient inﬂuenza virus replication to occur. Inﬂuenza
virus infected cells treated with LMB, an irreversible inhibitor
of XPO1, show a dose-dependent reduction in viral titre,
with complete inhibition of viral replication at 10 ng/ml
(Watanabe et al., 2008). LMB is an unsuitable drug candidate,
however, due to its irreversible binding to XPO1 and associated
potential toxicity. Recently a new class of orally available
SINE (Lapalombella et al., 2012) have been engineered which
form a slowly reversible covalent bond with XPO1, minimizing
cytotoxicity. The SINE compound Verdinexor has recently been
found inhibit the replication of various inﬂuenza A and B virus
strains in cell culture and reduce lung virus titres and associated
disease pathology in a mouse model with minimal cytotoxicity
(Perwitasari et al., 2014).
Screening for Inhibitors
The main challenge in looking for inhibitors that target
ubiquitous systems such as nucleocytoplasmic transport for
therapeutic intervention is cytotoxicity. Strategies to overcome
this include those where potential hit compounds can be
identiﬁed that speciﬁcally target the interface between viral and
host-cell proteins (e.g., IMP-viral protein or XPO-viral protein)
rather than the IMP or XPO directly, which would potentially
block transport of all host cell proteins that use the IMP/XPO
for normal traﬃcking. High-throughput screening where a
counterscreening strategy has been incorporated has proved
eﬃcacious in identifying compounds that have proved to be
speciﬁc inhibitors (Wagstaﬀ et al., 2011; Fraser et al., 2014), with
low toxicity and strong antiviral activity (Figure 3; Wagstaﬀ et al.,
2011, 2012, Fraser et al., 2014). Primary screening (Figure 3i)
is performed on a compound library to identify molecules that
disrupt the interaction between the viral protein-IMP/XPO of
interest, followed by speciﬁcity counter-screening (Figure 3iii)
to identify compounds that directly inhibit IMP/XPO function.
Only compounds shown to speciﬁcally inhibit viral protein-
IMP/XPO are selected for further cell based antiviral activity
analysis (Figure 3iv) and structural reﬁnement (Figure 3v;
structure/activity determination). Reﬁned molecules are re-
screened (Figure 3vi) to conﬁrm activity and speciﬁcity before
evaluation in animal models (Figure 3viii). This strategy has
been used successfully to identify antivirals targeting nuclear
import for HIV and DENV (Wagstaﬀ et al., 2011, 2012; Fraser
et al., 2014) – see next section – underlining its intrinsic
FIGURE 3 | High-throughput screening to identify specific agents
targeting nucleocytoplasmic transport that have antiviral activity.
High-throughput screening strategies to rapidly identify antiviral compounds that
specifically block viral:IMP/XPO/host protein interaction. (i) Primary screening is
performed using a chemical library to identify molecules that inhibit viral
protein-IMP/XPO interaction. (ii) Hits are counterscreened to identify
compounds that target IMP/XPO function directly, which although of interest for
research applications, are discarded from further examination in the pipeline
toward specific antivirals. (iii) Compounds not targeting IMP/XPO function but
rather specifically inhibiting viral protein:IMP/XPO interaction are screened in
cell-based assays (iv) to confirm antiviral activity. (v) Structure-activity
relationship analysis/focused library screening) is performed to optimize
properties of the inhibitor (e.g., pharmacodynamics) in multiple iterations (vi),
prior to evaluation of lead compounds in animal models of viral infection (vii).
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utility for future endeavors to develop eﬃcacious, non-toxic
antivirals.
Future Prospects
Since many RNA viruses rely on nuclear import of speciﬁc
viral gene products for eﬃcient replication, nucleocytoplasmic
transport of viral proteins represents a viable target for the
development of anti-virals, with all of the various interactions
listed in Table 1 thus at least in theory representing potential
targets for drug development. Targeting the host cell nuclear
import/export machinery itself can clearly have an eﬀect on
virus production (Ghildyal et al., 2009a; Prasetyo et al., 2009;
Rawlinson et al., 2009;Wagstaﬀ et al., 2012), but it is important to
recognize that, in general, targeting host cell proteins directly can
lead to toxicity (Newlands et al., 1996),. However, recent work
utilizing lower toxicity inhibitors of XPO1 (SINE compounds)
against inﬂuenza virus (Perwitasari et al., 2014) has progressed
into Phase I clinical trails, representing landmark studies in
the pursuit of antivirals directed at host nuclear transport
components. Drugs targeting viral proteins directly can select for
mutations that can reduce binding of anti-viral agents without
diminishing viral protein function too drastically (Johnson et al.,
2011; Kuritzkes, 2011; Skar et al., 2011; Lundgren and Lazarus,
2012). Targeting the viral protein:host protein interface (Loregian
et al., 2002) may be the most proﬁtable in terms of avoiding
issues of cytotoxicity, as well as limiting the possibilities for
viruses to mutate and still maintain viability. The recognition and
subsequent transport of cargo proteins across the NE requires
recognition of an NLS by its cognate IMP, with only very
minor changes in the NLS tolerated before nuclear transport
rates decline (Yang et al., 2010). This makes nucleocytoplasmic
transport an attractive therapeutic target, since selective pressure
to alter the NLS/NES to prevent drug binding are likely to result
in NLSs that are no longer able to be recognized by the host-cell
IMP/XPOs and thus fail to mediate eﬃcient nuclear transport.
Mifepristone is an example of a compound that speciﬁcally
inhibits HIV-1 IN:IMPα/β1 interaction (Wagstaﬀ et al., 2011),
and can inhibit HIV infection (Wagstaﬀ et al., 2012), whilst
recent work for dengue virus (DENV) shows that a speciﬁc
inhibitor [N-(4-hydroxyphenyl) retinamide] of DENV non-
structural protein ﬁve nuclear import through IMPα/β1 can
protect against infection by all four serotypes of DENV, including
severe, antibody-dependent enhanced disease in a lethal mouse
model (Fraser et al., 2014). Clearly, targeting the host-pathogen
interface in terms of nucleocytoplasmic transport represents an
exciting and viable avenue for the future development of novel
anti-viral drugs that are likely to be eﬃcacious and importantly,
highly speciﬁc (Perwitasari et al., 2014).
The approaches of Wagstaﬀ et al. (2011) and Fraser et al.
(2014) to derive speciﬁc inhibitors targeting the host-pathogen
interface used a counterscreening approach (Figure 3) to identify
all inhibitors that were likely to be directed against IMPs
rather than the host-virus interface; only compounds speciﬁcally
disrupting viral:host protein interaction were pursued, resulting
in successful and rapid identiﬁcation of the inhibitors that
ultimately proved to be highly speciﬁc for the host-virus interface.
This represents an exciting strategy in the future, potentially for
HRV 2A/3C nuclear import, for RSV M nuclear import and
export, and nuclear import/export of the various inﬂuenza virus
proteins. Targeting the viral protein-IMP (or viral protein-XPO)
interface in the case of these various proteins would appear to
be an exciting possibility, with great potential to generate novel,
speciﬁc antivirals with low toxicity, and little risk of selecting for
viral resistance.
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